Europe Developing Plan To Promote Med-Tech Innovation
This article was originally published in The Gray Sheet
Executive SummaryEuropean Union officials are developing an action plan for improving Europe's med-tech innovation landscape.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.